T1	intervention 0 9	Tamoxifen
T2	No-of-participants 473 478	13388
T3	eligibility 480 515	at increased risk for breast cancer
T4	outcome 1001 1043	reduced the risk of invasive breast cancer
T6	control 739 746	placebo
T7	control-participants 750 754	6707
T8	intervention-participants 782 786	6681
T9	duration 792 799	5 years
T11	control-value 1133 1137	43.4
T12	intervention-value 1145 1149	22.0
T13	outcome 1220 1234	decreased risk
T14	intervention-value 1279 1282	44%
T15	intervention-value 1298 1301	51%
T16	intervention-value 1327 1330	55%
T17	intervention-value 1409 1412	56%
T18	intervention-value 1439 1442	86%
T19	outcome 1511 1556	reduced the risk of noninvasive breast cancer
T20	intervention-value 1560 1563	50%
T21	outcome 1606 1653	occurrence of estrogen receptor-positive tumors
T22	intervention-value 1657 1660	69%
T23	intervention-participants 1154 1158	1000
T5	outcome 1078 1098	cumulative incidence
